Skip to main content
Premium Trial:

Request an Annual Quote

SeqWell, Gencove Partner on Low-Pass Sequencing Product

NEW YORK (GenomeWeb) — SeqWell and Gencove said today that they have agreed to combine certain of their respective technologies into a single product for low-pass whole-genome sequencing and genotype imputation.

Under the terms of the deal, the companies will join SeqWell's PlexWell multiplexed next-generation sequencing library preparation technology with Gencove's imputation and analysis software. Additional terms were not disclosed.

"This partnership will enable anyone with an Illumina sequencer to efficiently replace genotyping arrays with low-pass whole genome sequencing across applications, including genomic selection, marker assisted selection, QTL mapping, and genome-wide association studies," Gencove Cofounder and CEO Joe Pickrell said in a statement.

In late 2018, Gencove — a spinout of the New York Genome Center — formed an alliance with BGI Americas to combine technologies for a single low-pass sequencing service. Beverly, Massachusetts-based SeqWell rolled out PlexWell in 2017.